Andrographis, Andrographolide for Cold and Immune Multi-Target in 2025 Meta-Analysis
WELLNESS

Andrographis, Andrographolide for Cold and Immune Multi-Target in 2025 Meta-Analysis

By Sophie · · Phytomedicine 2025
KO | EN

Andrographis (Andrographis paniculata) standardized extract at 1.2g/day reduced cold recovery time by 1.85 days across 28 RCTs and 4,000 patients in a 2025 meta-analysis. Core immune herb of Indian Ayurveda + Chinese traditional medicine.

The Phytomedicine 2025 meta-analysis pooled 28 RCTs with 4,000 subjects. Cold symptom (throat, cough, runny nose, fever) recovery time -1.85 days, composite symptom score -42%, antibiotic use -38%, school/work absence -1.4 days. Doubles RCT count from Cochrane 2017.

What is Andrographis

Andrographis (Andrographis paniculata) is an Acanthaceae annual. English “Andrographis, Green Chiretta, King of Bitters”. Native to India and Southeast Asia, very bitter leaves (“king of bitters”). Sanskrit “Kalmegh” (dark cloud) — purification of subtle souls.

Active compound matrix:

  • Andrographolide: standardization marker, diterpenoid lactone, core active
  • Neoandrographolide, 14-deoxyandrographolide: secondary
  • Flavonoids: andrographolin, paniculin
  • Alkaloids: minor

3,000+ year tradition: core immune herb in Ayurveda, Chinese medicine, Thai traditional medicine. Widely used in 1919 India influenza pandemic. Listed in Indian ESCOP, Chinese Pharmacopoeia.

Multi-Target Mechanisms

1. Direct Immune Activation:

  • T cell, B cell activation
  • NK cell + neutrophil activity
  • IFN-γ + cytokine modulation (bidirectional)

2. Antiviral:

  • In vitro activity against influenza, HIV, dengue, herpes
  • Andrographolide partial viral protein synthesis inhibition
  • Some in vitro coronavirus activity (some SARS-CoV-2 trials)

3. Anti-inflammatory (Strong NF-κB Inhibition):

  • Direct NF-κB inhibition → cytokines ↓
  • Chronic inflammation + autoimmune support
  • One of the strongest anti-inflammatory plants

4. Liver Protection:

  • Hepatic glutathione + antioxidant
  • Alcohol/medication burden support
  • Some fatty liver support

5. Anti-Cancer (In Vitro/Animal):

  • Various cancer cell line in vitro
  • Andrographolide on NF-κB, STAT3 pathways
  • Clinical at supportive stage

Clinical Data

  • Phytomedicine 2025 meta-analysis 28 RCTs 4,000 subjects: cold recovery -1.85 days
  • Cochrane 2017: respiratory infection consistent effects
  • Indian trials: rheumatoid arthritis support
  • Thai/Chinese trials: chronic hepatitis support
  • COVID-19 trials (some): mild symptom recovery partial

Cautions

  • Pregnancy: avoid (uterine stimulation, miscarriage risk)
  • Lactation: limited data, avoid
  • Autoimmune disease: T/B cell activation can worsen (lupus, RA, MS)
  • Blood pressure medications: mild reduction, synergy possible
  • Glycemic medications: glucose reduction synergy possible
  • Anticoagulants: subtle effect possible
  • Liver medications: hepatic enzyme effects possible
  • 5~7 days short + rest: immune matrix burden, avoid long-term
  • Allergy: andrographolide allergy possible

Synergy Matrix

  • Echinacea + andrographis: classic immune (North America + India matrix)
  • Elderberry (L23) + andrographis: antiviral synergy
  • Vitamin D + zinc: immune foundation
  • NAC + andrographis: antioxidant + immune

Consumer Message

Cold, respiratory infection, chronic immune decline see antibiotics, antivirals as first-line, but resistance + burden invite alternatives. Andrographis offers core immune option from Ayurveda + Chinese medicine. Avoid in pregnancy/autoimmune absolutely, 5~7 days short + rest, autoimmune patients clinical evaluation. Spring/seasonal cold matrix. Synergy with echinacea, elderberry, vitamin D, zinc.